{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:18:16Z","timestamp":1793121496938,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.urolonc.2025.05.015","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T07:31:02Z","timestamp":1750404662000},"page":"525.e9-525.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Renin-angiotensin system inhibitors and survival in patients with renal cell carcinoma: Evidence from a meta-analysis"],"prefix":"10.1016","volume":"43","author":[{"given":"Hongyan","family":"Xi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingrui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8673-087X","authenticated-orcid":false,"given":"Jinhai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10451","key":"10.1016\/j.urolonc.2025.05.015_bib0001","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","article-title":"Renal cell carcinoma","volume":"404","author":"Young","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.urolonc.2025.05.015_bib0002","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.urolonc.2025.05.015_bib0003","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of renal cell carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur Urol."},{"issue":"8","key":"10.1016\/j.urolonc.2025.05.015_bib0004","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.05.015_bib0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of renal cell carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J Oncol."},{"issue":"6","key":"10.1016\/j.urolonc.2025.05.015_bib0006","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/HYPERTENSIONAHA.120.14820","article-title":"Association of hypertension and blood pressure with kidney cancer risk: a nationwide population-based cohort study","volume":"75","author":"Kim","year":"2020","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.urolonc.2025.05.015_bib0007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11523-014-0307-z","article-title":"Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial","volume":"10","author":"Rini","year":"2015","journal-title":"Target Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.05.015_bib0008","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/HYPERTENSIONAHA.120.16044","article-title":"New concept of onco-hypertension and future perspectives","volume":"77","author":"Kidoguchi","year":"2021","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.urolonc.2025.05.015_bib0009","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","article-title":"Cancer therapy-related hypertension: a scientific statement from the American Heart Association","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"key":"10.1016\/j.urolonc.2025.05.015_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.660943","article-title":"The use of antihypertensive drugs as coadjuvant therapy in cancer","volume":"11","author":"Carlos-Escalante","year":"2021","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.urolonc.2025.05.015_bib0011","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/14737140.2025.2463486","article-title":"Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence","volume":"25","author":"Wang","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"10.1016\/j.urolonc.2025.05.015_bib0012","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/14737140.2025.2464208","article-title":"Angiotensin system inhibitors improve survival in patients undergoing pancreatic cancer resection: a meta-analysis of real-world evidence","volume":"25","author":"Lin","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"issue":"11","key":"10.1016\/j.urolonc.2025.05.015_bib0013","article-title":"First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension","volume":"11","author":"Chen","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.urolonc.2025.05.015_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107527","article-title":"Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments","volume":"211","author":"Perini","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"19","key":"10.1016\/j.urolonc.2025.05.015_bib0015","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300706120","article-title":"Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells","volume":"120","author":"Gu","year":"2023","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"10.1016\/j.urolonc.2025.05.015_bib0016","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.immuni.2012.10.015","article-title":"Angiotensin II drives the production of tumor-promoting macrophages","volume":"38","author":"Cortez-Retamozo","year":"2013","journal-title":"Immunity"},{"issue":"16","key":"10.1016\/j.urolonc.2025.05.015_bib0017","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1158\/1078-0432.CCR-18-0236","article-title":"Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events","volume":"24","author":"Pinter","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2025.05.015_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1155104","article-title":"Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Shen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2025.05.015_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1378577","article-title":"Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"15","author":"Yu","year":"2024","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.05.015_bib0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11934-023-01160-x","article-title":"Role of the Renin-Angiotensin system components in renal cell carcinoma: a literature review","volume":"24","author":"Mour\u00e3o","year":"2023","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urolonc.2025.05.015_bib0021","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.urolonc.2025.05.015_bib0022","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.05.015_bib0023","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1634\/theoncologist.2012-0335","article-title":"Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with Sunitinib","volume":"19","author":"Keizman","year":"2014","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.urolonc.2025.05.015_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2016.12.016","article-title":"Angiotensin inhibitors as treatment of Sunitinib\/Pazopanib-induced hypertension in metastatic renal cell carcinoma","volume":"15","author":"Penttil\u00e4","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"13","key":"10.1016\/j.urolonc.2025.05.015_bib0025","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.ejca.2011.04.019","article-title":"Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination","volume":"47","author":"Keizman","year":"2011","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.urolonc.2025.05.015_bib0026","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/ijc.29972","article-title":"Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: a pooled secondary analysis of clinical trials","volume":"138","author":"Sorich","year":"2016","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.urolonc.2025.05.015_bib0027","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.urolonc.2025.05.015_bib0028","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s00432-019-02914-2","article-title":"Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation","volume":"145","author":"Neumann","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.05.015_bib0029","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejca.2021.08.036","article-title":"Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events","volume":"157","author":"Kostine","year":"2021","journal-title":"Eur J Cancer (1965)"},{"issue":"7","key":"10.1016\/j.urolonc.2025.05.015_bib0030","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1097\/HJH.0000000000002799","article-title":"Effect of concomitant use of antihypertensives and immune check point inhibitors on cancer outcomes","volume":"39","author":"Kichenadasse","year":"2021","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.urolonc.2025.05.015_bib0031","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.05.015_bib0032","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11523-021-00829-y","article-title":"Impact of concomitant cardiovascular medication on survival of metastatic renal cell carcinoma patients treated with Sunitinib or Pazopanib in the first line","volume":"16","author":"Fiala","year":"2021","journal-title":"Target Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.05.015_bib0033","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.clgc.2022.04.012","article-title":"Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors","volume":"20","author":"Nuzzo","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2025.05.015_bib0034","first-page":"313","article-title":"Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system","volume":"33","author":"Eskelinen","year":"2022","journal-title":"Cancer Causes Control"},{"issue":"7","key":"10.1016\/j.urolonc.2025.05.015_bib0035","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.1018892108","article-title":"Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors","volume":"108","author":"Diop-Frimpong","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.urolonc.2025.05.015_bib0036","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin-angiotensin system and cancer: old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2025.05.015_bib0037","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MOU.0000000000000603","article-title":"Gender-specific risk factors for renal cell carcinoma: a systematic review","volume":"29","author":"Lughezzani","year":"2019","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2025.05.015_bib0038","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.urolonc.2025.05.015_bib0039","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cellsig.2012.02.005","article-title":"Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium","volume":"24","author":"Carbajo-Lozoya","year":"2012","journal-title":"Cell Signal"},{"issue":"8","key":"10.1016\/j.urolonc.2025.05.015_bib0040","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.1002\/cam4.5734","article-title":"The impact of peroxisome proliferator-activated receptor-\u03b3 activating angiotensin receptor blocker on outcomes of patients receiving immunotherapy","volume":"12","author":"Chiang","year":"2023","journal-title":"Cancer Med"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:35:42Z","timestamp":1754912142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925002121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1078143925002121"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.05.015","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin-angiotensin system inhibitors and survival in patients with renal cell carcinoma: Evidence from a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}